* inability to take orally administered medication or food * known hypersensitivity to study medication * pregnant or lactating (unless practicing exclusive replacement feeding for the entire study duration) * participation in any other interventional trial for covid-19 (observational study co-enrollment allowed) * concurrent treatment with other agents with actual or possible direct-acting antiviral activity against sars-cov-2 less than 24 hours prior to study drug dosing * concurrent use of agents with known or uncertain interaction with study drugs, including ritonavir * requiring mechanical ventilation at screening * alanine aminotransferase (alt) or aspartate aminotransferase (ast) above 5 times upper limit of normal (uln) * creatinine clearance below 50 ml/min using the cockcroft-gault formula for participants above 18 years of age

* inability to take orally administered medication or food * known hypersensitivity to study medication * pregnant or lactating (unless practicing exclusive replacement feeding for the entire study duration) * participation in any other interventional trial for covid-19 (observational study co-enrollment allowed) * concurrent treatment with other agents with actual or possible direct-acting antiviral activity against sars-cov-2 less than 24 hours prior to study drug dosing * concurrent use of agents with known or uncertain interaction with study drugs, including ritonavir * requiring mechanical ventilation at screening * alanine aminotransferase (alt) or aspartate aminotransferase (ast) above 5 times upper limit of normal (uln) * creatinine clearance below 50 ml/min using the cockcroft-gault formula for participants above 18 years of age

- inability to take orally administered medication or food - known hypersensitivity to study medication - pregnant or lactating (unless practicing exclusive replacement feeding for the entire study duration) - participation in any other interventional trial for covid-19 (observational study co-enrollment allowed) - concurrent treatment with other agents with actual or possible direct-acting antiviral activity against sars-cov-2 less than 24 hours prior to study drug dosing - concurrent use of agents with known or uncertain interaction with study drugs, including ritonavir - requiring mechanical ventilation at screening - alanine aminotransferase (alt) or aspartate aminotransferase (ast) above 5 times upper limit of normal (uln) - creatinine clearance below 50 ml/min using the cockcroft-gault formula for participants above 18 years of age

- inability to take orally administered medication or food - known hypersensitivity to study medication - pregnant or lactating (unless practicing exclusive replacement feeding for the entire study duration) - participation in any other interventional trial for covid-19 (observational study co-enrollment allowed) - concurrent treatment with other agents with actual or possible direct-acting antiviral activity against sars-cov-2 less than 24 hours prior to study drug dosing - concurrent use of agents with known or uncertain interaction with study drugs, including ritonavir - requiring mechanical ventilation at screening - alanine aminotransferase (alt) or aspartate aminotransferase (ast) above 5 times upper limit of normal (uln) - creatinine clearance below 50 ml/min using the cockcroft-gault formula for participants above 18 years of age